Genomic testing plays a critical role in revealing the available treatment options for patients with metastatic NSCLC. In addition to directing patients toward targeted therapy options, appropriate molecular testing also avoids the ineffective use of immunotherapy that may cause future toxicity by introducing targeted therapy. Broad-based profiling can be performed in tissue or in blood as cfDNA. Mutational analyses in NSCLC should identify not only the aberrant gene (ie, the street name), but also the specific allele (ie, the numerical address). Genomic testing is here to stay, and its expanded role promises to improve outcomes for our patients by helping inform not only what we should do (eg, targeted therapy), but also what we should avoid (eg, immunotherapy for certain driver mutations).

Read more: https://dailynews.ascopubs.org/do/10.1200/ADN.22.201066/full/